- Home
- AACB vs AVIR Comparison
AACB vs AVIR Comparison
Compare AACB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACB
- AVIR
- Stock Information
- Founded
- AACB 2024
- AVIR 2012
- Country
- AACB United States
- AVIR United States
- Employees
- AACB N/A
- AVIR N/A
- Industry
- AACB
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- AACB
- AVIR Health Care
- Exchange
- AACB Nasdaq
- AVIR Nasdaq
- Market Cap
- AACB 298.1M
- AVIR 290.4M
- IPO Year
- AACB 2025
- AVIR 2020
- Fundamental
- Price
- AACB $10.13
- AVIR $3.30
- Analyst Decision
- AACB
- AVIR Hold
- Analyst Count
- AACB 0
- AVIR 1
- Target Price
- AACB N/A
- AVIR $6.00
- AVG Volume (30 Days)
- AACB 186.0
- AVIR 306.9K
- Earning Date
- AACB 01-01-0001
- AVIR 11-06-2025
- Dividend Yield
- AACB N/A
- AVIR N/A
- EPS Growth
- AACB N/A
- AVIR N/A
- EPS
- AACB N/A
- AVIR N/A
- Revenue
- AACB N/A
- AVIR N/A
- Revenue This Year
- AACB N/A
- AVIR N/A
- Revenue Next Year
- AACB N/A
- AVIR N/A
- P/E Ratio
- AACB N/A
- AVIR N/A
- Revenue Growth
- AACB N/A
- AVIR N/A
- 52 Week Low
- AACB $10.00
- AVIR $2.46
- 52 Week High
- AACB $11.35
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- AACB N/A
- AVIR 39.79
- Support Level
- AACB N/A
- AVIR $3.29
- Resistance Level
- AACB N/A
- AVIR $3.86
- Average True Range (ATR)
- AACB 0.00
- AVIR 0.14
- MACD
- AACB 0.00
- AVIR -0.03
- Stochastic Oscillator
- AACB 0.00
- AVIR 6.09
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).